Centre Jean PERRIN, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, F-63011, Clermont-Ferrand, France.
Délégation Recherche Clinique & Innovation, Centre Jean PERRIN, Centre de Lutte contre le Cancer, 58 rue Montalembert, F-63011, Clermont-Ferrand, France.
BMC Cancer. 2020 Feb 4;20(1):96. doi: 10.1186/s12885-020-6591-3.
A decrease in thermogenesis is suspected to be implicated in the energy expenditure reduction during breast cancer treatment. This study aimed to investigate the impact of chemotherapy on the metabolic activity of brown adipose tissue (BAT) and the link with weight variation.
This was an ancillary analysis of a multicentre trial involving 109 HER2+ breast cancer patients treated with neoadjuvant chemotherapy. A centralised review of F-FDG uptake intensity (SUV) in specific BAT regions (cervical and supraclavicular) was conducted on two PET-CT scans for each patient (before and after the first course of chemotherapy).
Overall, after one course of chemotherapy a significant decrease of 4.4% in F-FDG-uptake intensity was observed. It was not correlated to initial BMI, age or season. During chemotherapy, 10.1% (n = 11) of the patients lost weight (- 7.7 kg ± 3.8 kg; ie, - 9.4% ± 3.7%) and 29.4% (n = 32) gained weight (+ 5.1 kg ± 1.7 kg; ie, + 8.5% ± 2.6%). Among these subgroups, only the patients who had gained weight underwent a significant decrease (13.42%) in F-FDG uptake intensity (p = 0.042).
This study is the first to highlight in a large cohort of patients the negative impact of chemotherapy on brown adipose tissue activity. Weight gain during chemotherapy could thus potentially be explained in part by a decrease in brown adipose tissue activity.
据推测,乳腺癌治疗过程中热量生成的减少与能量消耗的减少有关。本研究旨在探讨化疗对棕色脂肪组织(BAT)代谢活性的影响及其与体重变化的关系。
这是一项涉及 109 例接受新辅助化疗的 HER2+乳腺癌患者的多中心试验的辅助分析。对每位患者的两次 PET-CT 扫描(化疗前和第一疗程后)中特定 BAT 区域(颈部和锁骨上)的 F-FDG 摄取强度(SUV)进行集中评估。
总体而言,在一个疗程的化疗后,观察到 F-FDG 摄取强度显著下降了 4.4%。它与初始 BMI、年龄或季节无关。在化疗期间,10.1%(n=11)的患者体重减轻(-7.7kg±3.8kg;即-9.4%±3.7%),29.4%(n=32)体重增加(+5.1kg±1.7kg;即+8.5%±2.6%)。在这些亚组中,只有体重增加的患者 F-FDG 摄取强度显著下降(13.42%)(p=0.042)。
本研究首次在大量患者中强调了化疗对棕色脂肪组织活性的负面影响。因此,化疗期间的体重增加可能部分归因于棕色脂肪组织活性的下降。